Art. 26 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 23×
1.

The marketing authorisation shall be refused if, after verification of the particulars and documents listed in Articles 8, 10, 10a, 10b and 10c, it is clear that:

(a)

the risk-benefit balance is not considered to be favourable; or

(b)

its therapeutic efficacy is insufficiently substantiated by the applicant; or

(c)

its qualitative and quantitative composition is not as declared.

2.

Authorisation shall likewise be refused if any particulars or documents submitted in support of the application do not comply with Articles 8, 10, 10a, 10b and 10c.

3.

The applicant or the holder of a marketing authorisation shall be responsible for the accuracy of the documents and the data submitted.

The 10 that are cited most themselves, of 23.

  • Directive (EU) 2004/27Lawamends

  • Judgment of the Court (First Chamber) of 9 June 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/03 to C-318/03) Decision

    Article 26 of that directive provides: ‘The marketing authorisation shall be refused if, after verification of the particulars and documents listed in Articles 8 and 10(1), it provides that: the medicinal product is harmful in the normal …

    9 Jun 2005 · 62003CJ0211

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    It should be noted in that regard that, according to Article 8(3)(e) and Article 11 of Directive 2001/83, which are also applicable to applications for marketing authorisation provided for in Article 6 of Regulation No 726/2004, such …

    14 Dec 2011 · 62009TJ0052

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decision

    Secondly, it is clear from Article 19(1) of Directive 2001/83 that, in order to examine an application under Article 10 of that directive, the competent authority of a Member State must verify whether the file submitted complies with that …

    14 Mar 2018 · 62016CJ0557

  • BVerwG, Urteil vom 1. Dezember 2016 - 3 C 14/15Decision

    … 2 AMG. Die Neufassung des § 25 Abs. 2 Satz 1 Nr. 5 AMG durch das 14. Arzneimitteländerungsgesetz setzte Art. 26 Abs. 1 Buchst. a der Richtlinie 2001/83/EG um. Eine inhaltliche Abweichung gegenüber der bislang geltenden Bestimmung war …

    1 Dec 2016 · WBRE201700245

  • Order of the President of the Court of First Instance of 24 April 2009. Nycomed Danmark ApS v Agence européenne des médicaments (EMEA).Decision

    24 Apr 2009 · 62009TO0052

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    In that regard, it must be stated that a medicinal product’s SmPC cannot but be interpreted strictly. Before granting an MA, including in the context of the variation or extension of an existing MA, the competent authority must ensure, …

    23 Sep 2020 · 62019TJ0549

  • Judgment of the General Court (Sixth Chamber) of 19 December 2019. Vanda Pharmaceuticals Ltd v European Commission.Decision

    It is apparent from a combined reading of Article 1(28a) and Article 26 of Directive 2001/83, as well as Article 12 of Regulation No 726/2004, read in the light of recital 14 of that regulation, that an MA is to be refused where, after …

    19 Dec 2019 · 62018TJ0211

  • BVerwG, Urteil vom 7. November 2019 - 3 C 19/18Decision

    … § 25 Abs. 2 Satz 1 Nr. 4 und Satz 3 AMG und Erwägungsgrund 7, Art. 26 Abs. 1 Buchst. b der Richtlinie 2001/83/EG). Er ist auf die klinische Prüfung der vom Arzneimittelhersteller beanspruchten Indikation bezogen (vgl. BVerwG, Urteil vom …

    7 Nov 2019 · WBRE202000139

  • Opinion of Mr Advocate General Geelhoed delivered on 3 February 2005. HLH Warenvertriebs GmbH (C-211/03) and Orthica BV (C-299/03 and C-316/Decision

    If a product falls within the Community definition of a medicinal product, then for market access purposes the provisions of Directive 2001/83 apply. According to the directive, a medicinal product may be placed on the market only if an …

    3 Feb 2005 · 62003CC0211